Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin 4 receptor (CD 124)

British Journal of Cancer

Volumn 73, Issue 4, 1996, Pages 429-432

  Tungekar, M F ^a   Gatter, K C ^b   Ritter, M A ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Adoptive immunotherapy; Bladder neoplasm; Interleukin 4; Interleukin 4 receptor; Mucosal immunity; Tumour targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; MUTANT PROTEIN; PROTEIN P53;

ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

EID: 0030019829     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.77     Document Type: Article

References (37)

1. AL JABAARI B, LADYMAN HM, LARCHE M, SIVOLAPENKO GB, EPENETOS AA AND RITTER MA. (1989). Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br. J. Cancer, 59, 910-914.
2. BUKOWSKI, RM, MCLAIN D, OLENCKI T, BUDD GT AND MURTHY SA. (1993). Interleukin-2: use in solid tumors. Stem Cells (Dayt)., 11, 26-32.
3. COLOMBO MP AND FORNI G. (1994). Cytokine transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today, 15, 48-51.
4. CORDELL JL, FALINI B, ERBER W, GHOSH A, ABDULAZIZ Z, MACDONALD S, PULFORD KAS, STEIN H AND MASON DY. (1984). Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP). J. Histochem. Cytochem., 32, 219-229.
5. COSTELLO R, LIPCEY C AND OLIVE D. (1993). Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy (review). Eur. J. Med., 2, 54-57.
6. DEBINSKI W, PURI RK, KREITMAN RJ AND PASTAN I. (1993). A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL-4 and Pseudomonas exotoxin. J. Biol. Chem., 268, 14065-14070.
7. De MAAGD RA, MACKENZIE WA, SCHUURMAN HJ, RITTER MA, PRICE KM, BROEKHUIZEN R AND KATER L. (1985). The human thymus microenvironment; heterogeneity detected by monoclonal antiepithelial antibodies. Immunology, 54, 745-754.
8. HERMANN GG, GEERTSEN PF, VON DER MAASE H, STEVEN K, ANDERSEN C, HALDT T AND ZEUTHEN J. (1992). Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res., 52, 726-733.
9. IMAMI N, LARCHE M AND RITTER MA. (1994). Inhibition of alloreactivity by monoclonal antibody MR6: differential effects on IL-2- and IL-4-producing human T-cells. Int. Immunol., 6, 1575-1584.
10. INTERNATIONAL UNION AGAINST CANCER. (1987). TNM Classification of Malignant Tumours. Springer: Berlin.
11. ISAKSON, P. (1992). Interleukin 4. Adv. Neuroimmunol., 2, 55-58.
12. JANSEN JH, FIBBE WE, WILLEMZE R AND KLUIN-NELEMANS JC. (1990). Interleukin-4. A regulatory protein. Blut, 60, 269-274.
13. KAKLAMANIS L, GATTER KC, MORTENSEN N AND HARRIS AL. (1992). Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br. J. Cancer, 66, 712-716.
14. KAWAKAMI Y. HAAS GP AND LOTZE MT. (1993). Expression of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J. Immunother., 14, 336-347.
15. KEEGAN AD AND PIERCE JH (1994). The interleukin-4 receptor: signal transduction by a hematopoietin receptor (review). J. Leukoc. Biol., 55, 272-279.
16. LAKKIS F, STEELE A, PACHECO-SILVA A, RUBIN-KELLEY V, STROM TB AND MURPHY JR. (1991). Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immuno-suppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur. J. Immunol., 21, 2253-2258.
17. LARCHÉ M, LAMB JR, O'HEHIR RE, IMAMI-SHITA N, ZANDERS ED, QUINT DE, MOQBEL R AND RITTER MA. (1988). Functional evidence for a monoclonal antibody that binds to the human interleukin-4 receptor. Immunology, 65, 617-622.
18. LOTZE MT, CUSTER MC, BOLTON HS, WIEBKE EA, KAWAKAMI Y AND ROSENBERG SA. (1990). Mechanisms of immunological antitumor therapy: lessons from the laboratory and clinical applications (review). Hum. Immunol., 28 (2), 198-207.
19. MAT I, LÄRCHE M, MELCHER D AND RITTER MA. (1990). Tumour-associated upregulation of the IL-4 receptor complex. Br. J. Cancer, 10 (suppl.) 96-98.
20. MAT IB, MOORS N, MELCHER D, FOXWELL BMJ AND RITTER MA. (1993). Differential expression of MR6 antigen and c-erbB-2 protein in breast tumours. In Mutant Oncogenes: Targets of Therapy. Lemoine N and Epenetos AA (eds) pp. 53-64. Chapman and Hall: London.
21. MORISAKI T, YUZUKI D, LIN RT, FOSHAG LJ, MORTON DL AND HOON DS. (1992). Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by interleukin 4. Cancer Res., 52, 6059-6065.
22. 1 cell cycle progression in gastric carcinoma cells. Cancer Res., 54, 1113-1118.
23. MOSTOFI FK, SOBIN LH AND TORLONI H (1973). Histological Typing of Urinary Bladder Tumors. International Classification of Tumors, No. 10. WHO: Geneva.
24. OBIRI N, HILLMAN GG, HAAS GP, SUD S AND PURI RK. (1993). Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest., 91, 88-93.
25. OBIRI N., SIEGEL JP, VARRICHIO F AND PURI RK. (1994). Expression of high affinity interleukin-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin. Exp. Immunol., 95, 148-155.
26. OZEN H. (1993). Advances in bladder cancer. Curr. Opin. Oncol., 5, 574-580.
27. PAUL WE. (1991). Interleukin 4: a prototypic immunoregulatory lymphokine. Blood, 77, 1859-1870.
28. PAUL WE AND SEDER RA. (1994). Lymphocyte responses and cytokines. Cell. 76, 241-251.
29. REDMOND HP, SCHUCHTER L, BARTLETT D, KELLY CJ, SHOU J, LEON P AND DALY JM. (1992). Anti-neoplastic effects of interleukin-4. J. Surg. Res., 52, 406-411.
30. RUSSEL SM, KEEGAN AD, HARADA H, NAKAMURA Y, NOGUCHI M, LELAND P, FRIEDMANN MC, MIYAJIMA A, PURI RK, PAUL WE AND LEONARD WJ. (1993). Interleukin-2 receptor γ chain: A functional component of the interleukin-4 receptor. Science, 262, 1880-1883.
31. STEWART TH AND TSAI SC. (1993). The possible role of stromal cell stimulation in worsening the prognosis of a subset of patients with breast cancer. Clin. Exp. Metastasis, 11, 295-305.
32. TEPPER RI. (1993). The anti-tumour and proinflammatory actions of IL4 (review). Res. Immunol., 144, 633-637.
33. TOI M, BICKNELL R AND HARRIS AL. (1992). Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res., 52, 275-279.
34. TOPP MS. KOENIGSMANN M, MIRE-SLUIS A, OBERBERG D, EITELBACH F, VON MARSCHALL Z, NOTTER M, REUFL B, STEIN H, THIEL E AND WOLFGANG EB. (1993). Recombinant human Interleukin 4 inhibits growth of some human lung tumor cell lines in vitro and in vivo. Blood. 82, 2837-2844.
35. TOTPAL K AND AGGARWAL BB. (1991). Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res., 51, 4266-4270.
36. TUNGEKAR MF, TURLEY H, DUNNILL MS, GATTER KC, RITTER MA AND HARRIS AL. (1991). Interleukin 4 receptor expression on human lung tumors and normal lung. Cancer Res., 51, 261-264.
37. VON GAUDECKER B, KENDALL MD AND RITTER MA. (1995). Immuno-electron microscopy of the thymic microenvironment. Microscopy Research and Technique (in press).